Terry Novak has over 30 years of experience in the pharmaceutical and biotech industries, most of that in executive leadership in business development, sales, marketing, and operations. Terry most recently served as the Chief Operating Office of Pernix Therapeutics, a publicly-traded specialty pharmaceutical company. Prior to joining Pernix, he spent 13 years as an executive in the pharmaceutical contract manufacturing industry at Norwich Pharmaceuticals, Patheon and DSM where he was responsible for global business development and manufacturing operations. Terry held executive level sales and marketing positions at Cytogen, Innovex and Bristol-Myers Squibb where he began his career as a sales representative. He has also served on the Board of Directors of Curaxis Pharmaceuticals, Pernix Ireland and Pernix Pain Ireland.
The government on Wednesday approved a programme for development of bio pharmaceuticals through industry-academia collaboration entailing investment of Rs 1,500 crore by it over a period of five years. The programme will focus on development of specific products such as vaccines, biotherapeutics, medical devices and diagnostics, an official statement said. Besides, the ‘Innovate in India empowering biotech entrepreneurs and accelerating inclusive innovation’ mission will also work on establishment of shared infrastructure and facilities.